LCTX vs WELL · rev $9.5M vs P/E 100, rev $10.84B
Lineage Cell Therapeutics Inc (LCTX) versus Welltower Inc (WELL) — a side-by-side from cached financials, not a winner call.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
Welltower Inc (WELL) is a reit - healthcare facilities company listed on NYSE.
Latest reported LCTX revenue for 2024-12-31 was $9.5M. Net income was -$18.6M. Revenue was up 354.9% from 2023-12-31 to 2024-12-31. LCTX currently screens at market cap $213.6M.
Latest reported WELL revenue for 2025-12-31 was $10.84B. Net income was $936.8M. Revenue was up 35.6% from 2024-12-31 to 2025-12-31. WELL currently screens at market cap $145.81B and trailing P/E 99.8.
LCTX currently screens at market cap $213.6M. WELL currently screens at market cap $145.81B and trailing P/E 99.8.
Not investment advice. Open the LCTX and WELL stock pages for the full models.
Not investment advice.